中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study

文献类型：期刊论文

作者Liu, Fuquan1; Ning, Zhenyuan2,3; Liu, Yanna2; Liu, Dengxiang4; Tian, Jie5; Luo, Hongwu6; An, Weimin7; Huang, Yifei2; Zou, Jialiang2; Liu, Chuan2
刊名EBIOMEDICINE
出版日期2018-10-01
卷号36页码:151-158
ISSN号2352-3964
关键词Portal hypertension Liver cirrhosis Hepatic venous pressure gradient Radioinics Noninvasive
DOI10.1016/j.ebiom.2018.09.023
通讯作者Ding, Huiguo(dinghuiguo@ccmu.edu.cn) ; Zhang, Yu(yuzhang@smu.edu.cn) ; Qi, Xiaolong(qixiaolong@vip.163.com)
英文摘要Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG >= 10 mm Hg) is invasive and therefore not suitable for routine clinical practice. This study aims to develop and validate a radiomics-based model as a noninvasive method for accurate detection of CSPH in cirrhosis. The prospective multicenter diagnostic trial (CHESS1701, ClinicalTrials.gov identifier: NCT03138915) involved 385 patients with cirrhosis from five liver centers in China between August 2016 and September 2017. Patients who had both HVPG measurement and contrast-enhanced CT within 14 days prior to the catheterization were collected. The noninvasive radiomics model, termed rHVPG for CSPH was developed based on Cr images in a training cohort consisted of 222 consecutive patients and the diagnostic performance was prospectively assessed in 163 consecutive patients in four external validation cohorts. rHVPG showed a good performance in detection of CSPH with a C-index of 0.849 (95%CI: 0.786-0.911). Application of rHVPG in four external prospective validation cohorts still gave excellent performance with the C-index of 0.889 (95%CI: 0.752-1.000,0.800 (95%CI: 0.614-0.986), 0.917 (95%CI: 0.772-1.000), and 0.827 (95%CI: 0.618-1.000), respectively. Intraclass correlation coefficients for inter- and infra-observer agreement were 0.92-0.99 and 0.97-0.99, respectively. A radiomics signature was developed and prospectively validated as an accurate method for noninvasive detection of CSPH in cirrhosis. The tool of rHVPG assessment can facilitate the identification of CSPH rapidly when invasive transjugular procedure is not available. (C) 2018 The Authors. Published by Elsevier B.V.
WOS关键词CHRONIC HEPATITIS-C ; PRESSURE-GRADIENT ; LIVER FIBROSIS ; ELASTOGRAPHY ; VARICES ; CANCER ; CARCINOMA ; BIOMARKER ; DISEASE ; IMAGES
资助项目National Natural Science Foundation of China[81600510] ; National Natural Science Foundation of China[81672725] ; Guangdong Science Fund for Distinguished Young Scholars[2018B030306019] ; Guangzhou Industry-Academia-Research Collaborative Innovation Major Project[201704020015] ; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation[pdjha0096] ; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding[ZYLX201610] ; Beijing Municipal Administration of Hospitals' Ascent Plan[DFL20151602] ; Application Research on Clinical Characteristics of the Capital[z161100000516197] ; Capital's Funds for Health Improvement and Research[2018-1-2081]
WOS研究方向General & Internal Medicine ; Research & Experimental Medicine
语种英语
出版者ELSEVIER SCIENCE BV
WOS记录号WOS:000447685300023
资助机构National Natural Science Foundation of China ; Guangdong Science Fund for Distinguished Young Scholars ; Guangzhou Industry-Academia-Research Collaborative Innovation Major Project ; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation ; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding ; Beijing Municipal Administration of Hospitals' Ascent Plan ; Application Research on Clinical Characteristics of the Capital ; Capital's Funds for Health Improvement and Research
源URL[http://ir.ia.ac.cn/handle/173211/23055]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Ding, Huiguo; Zhang, Yu; Qi, Xiaolong
作者单位1.Capital Med Univ, Beijing Shijitan Hosp, Dept Intervent Therapy, CHESS Grp, Beijing, Peoples R China
2.Southern Med Univ, State Key Lab Organ Failure Res, Inst Hepatol, CHESS Grp,Hepat Hemodynam Lab,Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
3.Southern Med Univ, Sch Biomed Engn, Guangzhou, Guangdong, Peoples R China
4.Xingtai Peoples Hosp, Xingtai Inst Canc Control, Xingtai, Peoples R China
5.Chinese Acad Sci, Key Lab Mol Imaging, Inst Automat, Beijing, Peoples R China
6.Cent S Univ, Dept Gen Surg, Xiangya Hosp 3, Changsha, Hunan, Peoples R China
7.302 Hosp PLA, Dept Radiol, Beijing, Peoples R China
8.Guangdong Acad Med Sci, Dept Radiol, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
9.302 Hosp PLA, Dept Gen Surg, Beijing, Peoples R China
10.Capital Med Univ, Dept Radiol, Beijing Youan Hosp, Beijing, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Fuquan,Ning, Zhenyuan,Liu, Yanna,et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study[J]. EBIOMEDICINE,2018,36:151-158.
APA Liu, Fuquan.,Ning, Zhenyuan.,Liu, Yanna.,Liu, Dengxiang.,Tian, Jie.,...&Qi, Xiaolong.(2018).Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.EBIOMEDICINE,36,151-158.
MLA Liu, Fuquan,et al."Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study".EBIOMEDICINE 36(2018):151-158.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。